![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, January 18, 2018 11:54:01 AM
Biotica is positioning to be a world-class research and development facility in endocannabinoid drug development. Biotica has set-up a state-of-the-art research and development lab to enhance the BPRxTM platform and is rapidly expanding its research capabilities. Biotica’s research includes specific programs for eosinophilic esophagitis, Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease and severe, chronic pain. For each of these diseases, there is a dire need for new therapies. Depending on the disease, our therapies will use a BPRxTM platform to optimize the synergistic combination of phyto and endocannabinoids to modulate disease pathology and progression. By significantly decreasing the production of relevant signaling and causative molecules at targeted sites within various tissue systems, the goal is to address the underlying biology of the disease and make a meaningful difference for patients. Our talented team of scientists, scientific advisers, and board directors are working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Sam Talari provided a link on his LinkedIn profile
https://www.linkedin.com/feed/update/activity:6354314628218048512/
https://globenewswire.com/news-release/2018/01/03/1281500/0/en/Dr-Paul-Carney-Joins-Biotica-Pharmaceuticals-as-Neurologist-Consultant-and-Scientific-Advisor.html
$IFXY
Cryptocurrency Corp
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM